Pembrolizumab immune checkpoint inhibition

MK-3475 - Keytruda - lambrolizumab



Trial Studied treatment Control Patients Size Study type Results NCT

Gastric or gastro-oesophageal junction cancer (advanced) - immune checkpoint inhibition in all type of patients

KEYNOTE-059pembrolizumabnilNA NCT02335411
Keynote 061, 2018pembrolizumabpaclitaxel2LNA Confirmatory - NCT02370498

Head and neck cancer - immune checkpoint inhibition in all type of patients

KEYNOTE-048 ongoing pembrolizumabCetuximab + Platinum + 5FU1LNA NCT02358031
KEYNOTE-040pembrolizumabstandard treatment2LNA Confirmatory - NCT02252042
Keynote 147 ongoing pembrolizumab +/- acalabrutinibstandard treatment>2LNA NCT02454179

Lung cancer (metastatic) - immune checkpoint inhibition in all type of patients - immune checkpoint inhibition in second line - immune checkpoint inhibition in first line - immune checkpoint inhibition in first line

Keynote 024, 2015pembrolizumabplatinum-based CT1L, PDL1 positive305 (154/151) Confirmatory - NCT02142738
Keynote 042 (>=1%), 2018pembrolizumabplatinum-based CT1L, PDL1 positive1274 (637/637) Confirmatory - NCT02220894
Keynote 042 (>=20%), 2018pembrolizumabplatinum-based CT1L, PDL1 positive818 (413/405) Confirmatory - NCT02220894
Keynote 042 (>=50%), 2018pembrolizumabplatinum-based CT1L, PDL1 positive599 (299/300) NCT02220894
Keynote 189, 2018pembrolizumab + platinum-based CTplatinum-based CT1L PD-L1 positive nonsquamous616 (410/206) Confirmatory NCT02578680
KEYNOTE-021 phase 2, 2016pembrolizumab + platinum-based CTplatinum-based CT1L nonsquamous123 (60/63) Exploratory NCT02039674
Keynote 010 10mg, 2015pembrolizumab 10mgdocetaxel2L, PD-L1 positive689 (346/343) Confirmatory - NCT01905657
Keynote 010 2mg, 2015pembrolizumab 2mgdocetaxel2L, PD-L1 positive688 (345/343) Confirmatory - NCT01905657
Keynote 407, 2018pembrolizumanb + CTplatinum-based CT1L squamous559 (278/281) Confirmatory - NCT02775435

Melanoma - immune checkpoint inhibition in all type of patients - immune checkpoint inhibition in second line (or later) - immune checkpoint inhibition in first line - immune checkpoint inhibition in adjuvant setting - All mechanism in adjuvant setting - A EFFACER in adjuvant 1 - NOVARTIS - Miscellaneous in adjuvant stage III only - NOVARTIS

KEYNOTE-054, 2018pembrolizumabplaceboadjuvant1019 (514/505) Confirmatory NCT02362594
KEYNOTE-006 (every 2W), 2015pembrolizumab (every 2W)ipilimumab1LNA Confirmatory - NCT01866319
KEYNOTE-006 (every 3W), 2015pembrolizumab (every 3W)ipilimumab1L555 (277/278) Confirmatory - NCT01866319
KEYNOTE 002 (10mg/kg Q3W), 2015pembrolizumab 10mg/kgchemotherapy2L360 (181/179) Exploratory NCT01704287
KEYNOTE 002 (2mg/kg Q3W), 2015pembrolizumab 2mg/kgchemotherapy2L359 (180/179) Exploratory NCT01704287
KEYNOTE-001, 2014pembrolizumab 2mg/kgpembrolizumab 10mg/kg2L173 (89/84) Exploratory NCT01295827

Multiple myeloma - immune checkpoint inhibition in all type of patients

KEYNOTE-183, 2018pembrolizumab + pomadoline + dexamethasonepomadoline + dexamethasonerrMM249 (125/124) Confirmatory - NCT02576977
KEYNOTE-185, 2018pembrolizumab, lenalidomide, dexametahsonelenalidomide, dexamethasonenot eligible for ASCT301 (151/150) Confirmatory - NCT02579863

Renal-cell carcinoma (advanced) - immune checkpoint inhibition in all type of patients

KEYNOTE-426 ongoing pembrolizumab + axitinibsunitinibNA NCT02853331

Urothelial carcinoma (advanced) - immune checkpoint inhibition in all type of patients

KEYNOTE-052, 2017pembrolizumabNA Exploratory NCT02335424
KEYNOTE-045, 2017pembrolizumabchemotherapy2nd line542 (270/272) Confirmatory - NCT02256436
Keynote 361 monotherapypembrolizumabchemotherapyfirst line990 NCT02853305
Keynote 361 combination ongoing pembrolizumab + CTchemotherapyfirst lineNA NCT02853305



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons